-
Mashup Score: 25Optimizing Salvage Radiation Therapy in Prostate Cancer: New AUA/ASTRO/SUO Guideline - Todd Morgan - 4 hour(s) ago
Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate AI test, highlighting its use in identifying biochemical recurrence after prostatectomy. This AI model, validated with data from key trials, not only distinguishes patients based on the aggressiveness of their disease…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4Collaborating on Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Daniel Saltzstein - 5 hour(s) ago
Zach Klaassen converses with Daniel Saltzstein about the collaborative approach in treating metastatic hormone-sensitive prostate cancer with triplet therapy. Dr. Saltzstein describes their unique setup in San Antonio, where a medical oncologist is part of their urology team, facilitating seamless collaboration and treatment intensification. They focus on identifying high-volume, high-risk…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Daniel Saltzstein, MD @UrologySA joins @zklaassen_md @GACancerCenter to discuss the collaborative strategy for treating #mHSPC π€ He emphasizes clear communication and a multidisciplinary team for optimal patient outcomes > https://t.co/evby5rjpRr @BayerUS https://t.co/fTDq4SEdme
-
-
Mashup Score: 4Urology-Oncology Collaboration: Keys to Optimal Care in Metastatic Prostate Cancer - Damian Sorce & Manojkumar Bupathi - 6 hour(s) ago
Alicia Morgans hosts a discussion with Damian Sorce, a urologist, and Manoj Bupathi, a medical oncologist, on their collaboration in treating patients with metastatic hormone-sensitive prostate cancer. Dr. Sorce shares a case of a newly diagnosed patient with advanced disease, emphasizing the importance of immediate communication and coordination between urology and medical oncology for starting…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Urology-oncology collaboration: Keys to optimal care in metastatic #ProstateCancer. Damian Sorce @ColoradoUro & Manojkumar Bupathi joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/cEc3AUmE8t @BayerPharma https://t.co/Q6lfxCxTZu
-
-
Mashup Score: 8Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie - 7 hour(s) ago
Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Innovative trials highlight progress in treating #UrothelialCarcinoma at #AUA24. Karim Chamie, MD, MSHS @UclaUrology joins @UroCancerMD @VUMCurology to discuss improving treatment strategies and personalizing therapy based on risk stratification > https://t.co/oe5NV1bmXO https://t.co/u8YlCROSlv
-
-
Mashup Score: 15Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson - 7 hour(s) ago
Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer. Cretostimogene, an oncolytic adenovirus, selectively targets and destroys cancer cells while sparing normal tissue and boosting antitumor immunity. The phase III study reported a 75.2% complete response rate,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Breaking Paradigms: #Cretostimogene monotherapy #BOND-003 demonstrates significant durability & tolerability with no major AEs. @FDA grants Fast Track & Breakthrough Therapy designation. @MarkTysonMD discusses on UroToday > https://t.co/yZi3tr3acl #BladderCancer @cgoncology https://t.co/rkt3NTS77N
-
-
Mashup Score: 3The Impact of Advanced Imaging on Detection and Treatment in Nonmetastatic CRPC - Vahan Kassabian - 7 hour(s) ago
Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel imaging techniques, particularly PSMA PET scans, have significantly narrowed the nmCRPC space by identifying metastases not detected by traditional imaging. Dr. Kassabian highlights the importance of PSA…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The Impact of advanced imaging on detection and treatment in nonmetastatic #CRPC. @DrKgusurgeon @AdvancedUroGA joins @zklaassen_md @GACancerCenter in a discussion on the evolving landscape of #nmCRPC management > https://t.co/Lin8GJZmsy @BayerUS https://t.co/aHXIoLA1rM
-
-
Mashup Score: 2
Other than staying on drug, there’s no evidence-based strategy to maintain weight loss
Source: www.medpagetoday.comCategories: General Medicine News, General NewsTweet-
"Chronic diseases require chronic treatment." -- @drchefnate, of @YaleMed, on patients regaining weight after stopping #GLP1 drugs. https://t.co/jlOJrNDhWV
-
-
Mashup Score: 0Monster MASH Mondays: Why You Need to be Aware of MASH - 10 hour(s) ago
Join us every Monday in October for the latest in metabolic dysfunction-associated steatohepatitis (MASH)!In the first 15-minute episodeβOctober 7 at 8:00pm …
Source: www.youtube.comCategories: General Medicine News, General NewsTweet-
Monster MASH Mondays start TOMORROW! Don't be π πππππ to learn the basics of this underdiagnosed chronic liver disease. WATCH LIVE as @AlkhouriNaim + @jay_shubrook explain ππ ππ’π π‘ 15 ππππ’π‘ππ how + why to screen your patients! π https://t.co/nZ2CBOFjhh https://t.co/LAFDBbfedh
-
-
Mashup Score: 7Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich - 22 hour(s) ago
John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company’s “radioligand first, isotope second” approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advancing #Radiopharmaceuticals: Targeting strategies and isotope selection in cancer therapy. John Babich, PhD @Ratio_Tx and Oliver Sartor, MD @MayoClinic emphasize the importance of targeting and retention in tumor tissues > https://t.co/9wfv2h5NCt https://t.co/WqTfXEhDla
-
-
Mashup Score: 16Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li - 24 hour(s) ago
Roger Li discusses findings from a patient panel at the BCAN Think Tank, focusing on decision-making in BCG-unresponsive and muscle-invasive bladder cancer treatment. He emphasizes the emotional journey patients undergo and the importance of empowering them with information. Dr. Li highlights several patient stories, demonstrating diverse treatment choices ranging from bladder-sparing approaches…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Patient perspectives on #BladderCancer: Balancing treatment options and shared decision-making. @UrogerliMD @MoffittNews joins @UroDocAsh @MDAndersonNews discussing findings from a patient panel at #BCANTT24 on BCG-unresponsive and #MIBC > https://t.co/32l0Ru0lek @BladderCancerUS https://t.co/EKYoJVG2f7
-
Optimizing salvage radiation therapy in #ProstateCancer: New AUA/ASTRO/SUO Guideline. @wandering_gu @UMichUrology joins @zklaassen_md @GACancerCenter in this discussion of innovative approaches to prostate cancer management on UroToday > https://t.co/pGF8HGBYeF https://t.co/iKOl6ps4XY